-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Odyssey Health, Inc. Makes Statement Regarding Its Concussion Drug Development Program
Odyssey Health, Inc. Makes Statement Regarding Its Concussion Drug Development Program
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the "Company" "Odyssey") a company focused on developing a unique drug to treat concussion has decided to dissolve its sports advisory board.
The sports advisory members have been outspoken advocates for concussion prevention and for the importance of finding responsible treatments. We created the advisory board to increase awareness of our mission to bring a much-needed pharmaceutical for a condition that currently has no FDA approved treatment. We have recently completed a Phase I human trial where our drug was proven to be safe and well tolerated. We are excited about the potential of initiating a Phase II trial to determine the efficacy and safety of the drug in concussed patients.
The press has misrepresented Odyssey Health, Inc. Odyssey has never directly or indirectly received money from state or federal government sources to fund the drug development. Odyssey is not involved in any litigation. Odyssey Health, Inc. purchased the intellectual property and rights to the drug on March 1, 2021. The money to fund the drug development has come from accredited investors. The Company contacted the press to advise of the facts and misstatements.
In order to keep our focus, the Company has decided to dissolve the sports advisory board, as it has caused distraction to our critical work being done. Odyssey wants to continue its focus on this important drug candidate in hopes of providing a much-needed treatment. The Company will remain committed to bringing products to market that provide a solution to unmet medical needs.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company's website at .
About PRV-002
PRV-002 is a fully synthetic, non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the "Company" "Odyssey") a company focused on developing a unique drug to treat concussion has decided to dissolve its sports advisory board.
內華達州拉斯維加斯,9月2022年30日(環球網)--奧德賽健康公司(OTC:ODYY),F/K/a奧德賽集團國際有限公司(簡稱“公司”)一家專注於開發一種治療腦震盪的獨特藥物的公司決定解散其體育顧問委員會。
The sports advisory members have been outspoken advocates for concussion prevention and for the importance of finding responsible treatments. We created the advisory board to increase awareness of our mission to bring a much-needed pharmaceutical for a condition that currently has no FDA approved treatment. We have recently completed a Phase I human trial where our drug was proven to be safe and well tolerated. We are excited about the potential of initiating a Phase II trial to determine the efficacy and safety of the drug in concussed patients.
體育顧問成員一直是腦震盪預防和找到負責任治療的重要性的直言不諱的倡導者。我們成立了顧問委員會,以提高人們對我們使命的認識,我們的使命是為目前沒有FDA批准的治療方法的疾病帶來急需的藥物。我們最近完成了一期人體試驗,我們的藥物被證明是安全和耐受性良好的。我們對啟動第二階段試驗以確定該藥物在腦震盪患者中的有效性和安全性的潛力感到興奮。
The press has misrepresented Odyssey Health, Inc. Odyssey has never directly or indirectly received money from state or federal government sources to fund the drug development. Odyssey is not involved in any litigation. Odyssey Health, Inc. purchased the intellectual property and rights to the drug on March 1, 2021. The money to fund the drug development has come from accredited investors. The Company contacted the press to advise of the facts and misstatements.
媒體歪曲了奧德賽健康公司的説法。奧德賽從未直接或間接從州或聯邦政府來源獲得資金,以資助藥物開發。奧德賽沒有捲入任何訴訟。奧德賽健康公司於2021年3月1日購買了該藥物的知識產權和權利。為藥物開發提供資金的資金來自經過認可的投資者。該公司聯繫了媒體,告知事實和錯誤陳述。
In order to keep our focus, the Company has decided to dissolve the sports advisory board, as it has caused distraction to our critical work being done. Odyssey wants to continue its focus on this important drug candidate in hopes of providing a much-needed treatment. The Company will remain committed to bringing products to market that provide a solution to unmet medical needs.
為了保持我們的注意力,公司決定解散體育顧問委員會,因為這會分散我們正在進行的關鍵工作的注意力。奧德賽希望繼續專注於這一重要的候選藥物,希望提供急需的治療。該公司將繼續致力於將產品推向市場,為未滿足的醫療需求提供解決方案。
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company's website at .
關於奧德賽健康公司(前身為奧德賽國際集團)
奧德賽健康公司(場外交易代碼:ODYY)是一家專注於拯救生命的醫療解決方案領域的醫療公司。奧德賽的公司使命是創造、收購和開發獨特的資產、知識產權和特殊技術,提供有意義的醫療解決方案。該公司專注於具有公認的技術優勢、提供卓越的臨牀實用價值和具有重大市場機會的領域。欲瞭解更多信息,請訪問該公司網站:.
About PRV-002
PRV-002 is a fully synthetic, non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
關於PRV-002
PRV-002是一種完全合成的、非自然產生的神經類固醇,正在開發用於治療腦震盪。在臨牀前研究中,PRV-002已經證明瞭與相關神經類固醇相比,即使不是更好,也有同等的神經保護作用。腦震盪的動物模型表明,PRV-002可以減少與腦損傷症狀相關的行為病理,如記憶障礙、焦慮和運動/感覺表現。此外,PRV-002是親脂性的,可以很容易地穿過血腦屏障,在恢復正常血液流動的同時,迅速消除大腦中的腫脹、氧化應激和炎症。
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof.
前瞻性陳述
本新聞稿可能包含1995年私人證券訴訟改革法中“安全港”條款所指的前瞻性陳述。此類陳述是基於我們目前的預期,僅代表截至本文發佈之日的情況。
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
查詢:
奧德賽健康
電子郵箱:Info@odyseyHealth Thinc.com
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧